Soligenix, Inc. (NASDAQ:SNGX) Short Interest Down 20.2% in November

Soligenix, Inc. (NASDAQ:SNGX) saw a large decline in short interest in November. As of November 30th, there was short interest totalling 36,700 shares, a decline of 20.2% from the November 15th total of 46,000 shares. Currently, 1.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 113,000 shares, the short-interest ratio is currently 0.3 days.

Hedge Funds Weigh In On Soligenix

An institutional investor recently bought a new position in Soligenix stock. Armistice Capital LLC purchased a new position in shares of Soligenix, Inc. (NASDAQ:SNGX) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 80,000 shares of the biopharmaceutical company’s stock, valued at approximately $206,000. Armistice Capital LLC owned approximately 8.11% of Soligenix as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 3.60% of the company’s stock.

Soligenix Stock Down 2.9 %

Shares of SNGX stock traded down $0.09 on Monday, reaching $3.07. The company had a trading volume of 106,943 shares, compared to its average volume of 774,801. The business’s 50-day moving average is $3.57 and its 200 day moving average is $3.91. Soligenix has a one year low of $1.83 and a one year high of $19.20. The stock has a market capitalization of $7.71 million, a PE ratio of -0.42 and a beta of 1.79.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.